Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT05382442	TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2022-05-19	Ubicación California, United States China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas 5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin	Etiquetas MSS/ MMRp
NCT ID NCT05382741	TitleAdjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial	Fase Fase 2	Date Added 2022-05-19	Ubicación Italia	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga	Etiquetas MSS/ MMRp
NCT ID NCT05350917	TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy	Fase Fase 2	Date Added 2022-04-28	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas Tislelizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05349890	TitlePersonalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)	Fase Fase 1	Date Added 2022-04-27	Ubicación Oregon, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas CDX-1140, Pembrolizumab, Keytruda	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05333809	TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2022-04-19	Ubicación	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas Disitamab vedotin, Pembrolizumab, Keytruda	Etiquetas MSS/ MMRp
NCT ID NCT05328908	TitleUn estudio de combinación de dosis fija de nivolumab-relatlimab frente a regorafenib o TAS-102 en participantes con cáncer colorrectal metastásico de última línea	Fase Fase 3	Date Added 2022-04-14	Ubicación Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Bélgica Canadá Chile China Czechia Francia Alemania Italia Japón Corea, República de Países Bajos Polonia Puerto Rico Singapur España Suecia Suiza Taiwán	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga	Etiquetas MSS/ MMRp
NCT ID NCT05319314	TitleGCC19CART for Patients With Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2022-04-08	Ubicación California, United States Colorado, United States Massachusetts, United States Michigan, United States Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas GCC19CART	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05308446	TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	Fase Fase 2	Date Added 2022-04-04	Ubicación Arizona, United States California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo	Etiquetas MSS/ MMRp
NCT ID NCT05299840	TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer	Fase No aplicable	Date Added 2022-03-29	Ubicación Francia	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05292417	TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC	Fase Fase 2	Date Added 2022-03-23	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Fruquintinib, GM-CSF, Sintilimab	Etiquetas MSS/ MMRp

Showing 101 to 110 of 299 entries